After several subdued years, M&A activity in the life sciences sector has rebounded strongly in 2026. With major pharma companies facing an approaching patent cliff, the race is on to replenish pipelines and secure the next generation of high-value medicines.
In this episode of Life Sciences: Lab notes from Bristows, Nick Cross and Ben Lammin explore what is driving the resurgence in dealmaking, why buyers are increasingly willing to invest in earlier-stage assets, and which therapeutic areas are attracting the most attention.#
Listen above, on Apple Podcasts or Spotify.
All information was correct at the time of recording.

/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2025-09-29-13-48-10-128-68da8e1af6347a2c4b96de4e.png)
/Passle/5f3d6e345354880e28b1fb63/SearchServiceImages/2026-11-12-17-32-40-845-6af5f8381d08c17997a20ca9.jpg)
/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2024-08-23-11-31-07-354-66c872fb971eecc249d83d40.png)
/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2024-08-01-13-11-10-549-66ab896ee543bf94f9636c73.png)